Lenalidomide Plus Rituximab vs Rituximab–Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Journal of Clinical Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Six-Year Results From RELEVANCE: Lenalidomide Plus Rituximab (R2) Versus Rituximab-Chemotherapy Followed by Rituximab Maintenance in Untreated Advanced Follicular Lymphoma
J. Clin. Oncol 2022 Aug 10;[EPub Ahead of Print], F Morschhauser, L Nastoupil, P Feugier, JM Schiano de Colella, H Tilly, ML Palomba, E Bachy, C Fruchart, EN Libby, RO Casasnovas, IW Flinn, C Haioun, H Maisonneuve, L Ysebaert, NL Bartlett, K Bouabdallah, P Brice, V Ribrag, S Le Gouill, N Daguindau, S Guidez, GM Pica, AM García-Sancho, A López-Guillermo, JF Larouche, K Ando, M Gomes da Silva, M André, W Kalung, LH Sehn, K Izutsu, G Cartron, A Gkasiamis, R Crowe, L Xerri, NH Fowler, G SallesFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.